Monevue Monevue

Roivant Sciences Ltd.
ROIV 12.50 Stock Price Roivant Sciences Ltd.

Home
  /  
Stock List  /  Roivant Sciences Ltd.
Range:8.611-13.055Vol Avg:6070481Last Div:0Changes:0.71
Beta:1.24Cap:9.12BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Tue Dec 08 2020Empoloyees:908
CUSIP:G76279101CIK:0001635088ISIN:BMG762791017Country:GB
CEO:Mr. Matthew GlineWebsite:https://roivant.com
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Stock Details

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Positive 0.50

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

seekingalpha.com·Tue Nov 12 2024
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates
Negative -0.33

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

zacks.com·Tue Nov 12 2024
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Neutral 0.00

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

globenewswire.com·Tue Oct 29 2024
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Positive 0.20

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

globenewswire.com·Mon Oct 28 2024
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Positive 0.19

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

seekingalpha.com·Tue Oct 22 2024
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Positive 0.30

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

benzinga.com·Wed Sep 18 2024
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Positive 0.50

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

globenewswire.com·Wed Sep 18 2024
Monevue Monevue

About The Monevue

Stock News

Markets

Best Buys

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection Status • Powered by StackThrow